362606-12-0 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
C-ISOQUINOLIN-8-YL-METHYLAMINE is utilized as a key intermediate in the synthesis of new drugs and potential therapeutic agents due to its unique structural properties that contribute to the biological activity of the resulting compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, C-ISOQUINOLIN-8-YL-METHYLAMINE serves as an important building block for the creation of novel drug candidates, facilitating the design and synthesis of molecules with specific therapeutic targets.
Used in Chemical Biology:
C-ISOQUINOLIN-8-YL-METHYLAMINE may also find applications in chemical biology, where it could be employed to study the interactions between small molecules and biological targets, potentially leading to the discovery of new bioactive molecules.
Used in Organic Synthesis:
C-ISOQUINOLIN-8-YL-METHYLAMINE may be utilized in various organic synthesis processes, providing a versatile starting material for the preparation of a range of organic compounds with potential applications in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 362606-12-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,2,6,0 and 6 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 362606-12:
(8*3)+(7*6)+(6*2)+(5*6)+(4*0)+(3*6)+(2*1)+(1*2)=130
130 % 10 = 0
So 362606-12-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H10N2/c11-6-9-3-1-2-8-4-5-12-7-10(8)9/h1-5,7H,6,11H2
362606-12-0Relevant articles and documents
AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
, (2016/06/21)
Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
THROMBIN INHIBITORS
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of D, E, F, G, H, I, and J are independently N or CY 1, provided that the number of such variables D, E, F, G, H, I, and J representing N is 0, 1, or 2; K, L, M and Q are independently NH or CY1Y2, provided that the number of such variables D, E, F, K, L, M, and Q representing N is 0, 1, or 2; Y1 and Y2 are independently selected from the group consisting of hydrogen, C1-4 alkyl, halogen, anino, or hydroxy; A is
